Cho‐Ming Loi
PharmacoGenetics (China)(CN)
Publications by Year
Research Areas
Pharmacogenetics and Drug Metabolism, HER2/EGFR in Cancer Research, Drug Transport and Resistance Mechanisms, Cancer Treatment and Pharmacology, Advanced Breast Cancer Therapies
Most-Cited Works
- → Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth(2010)320 cited
- → Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor(2008)221 cited
- → Hepatic Drug Metabolism and Aging(1990)204 cited
- → Assessment of Three Human in Vitro Systems in the Generation of Major Human Excretory and Circulating Metabolites(2009)185 cited
- → In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration(2001)134 cited
- → Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration(2006)125 cited
- → Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans(2007)117 cited
- → Clinical Pharmacokinetics of Troglitazone(1999)115 cited
- → Roles of Exercise and Pharmacokinetics in Cerivastatin-Induced Skeletal Muscle Toxicity(2005)75 cited